Delivery Order SPE2DU25D9439-SPE2DU26FEEFF

The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,178.57 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This firm fixed-price delivery order, issued on January 23, 2026, with an ultimate completion date of January 26, 2026, was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA—specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative—which was awarded in November 2025 with a $499.999 billion ceiling and extends through December 31, 2036.

DMS Pharmaceutical Group serves as a critical pharmaceutical supplier for Department of Defense healthcare operations, distributing a comprehensive range of products including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and specialty pharmaceuticals to military healthcare facilities worldwide. The PPV-G GEN V represents part of the DLA's broader $30.3 billion pharmaceutical supply chain modernization strategy, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors responsible for fulfilling the diverse and specialized pharmaceutical requirements of the federal military medical system. The company's established performance on numerous prior delivery orders and its single-award IDC status underscore its capability to meet the complex pharmaceutical needs of DoD healthcare operations.